39 results about "Polycystic kidney" patented technology

Lonidamine derivatives can be useful in methods of treating, inhibiting, and / or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and / or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and / or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.

Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder.

A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.

Provided are methods of treating polycystic kidney disease in a subject in need thereof, by administering to the subject in need thereof, an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods of treating polycystic kidney disease by a compound of formula (I) in combination with additional therapeutic agents.

The invention discloses a novel Chinese medicinal composition for treating renal cyst diseases and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: mix-fried pangolin scales, tangerine peel, Chinese angelica, immature bitter orange, common burreed rhizome, zedoary, turmeric root-tuber, peach seed, safflower, turtle shell, tortoise plastron, Szechuan lovage rhizome, red paeony root, dragon's blood, Chinese eaglewood, green tangerine peel, root of red-rooted salvia, Indian buead, oriental waterplantain rhizome, cortex lycii radicis, amur corktree bark, gardenia, Vietnamese sophora root, raw rehmannia root, liriope, coridius, nutgrass galingale rhizome, medicated leaven and plantain seed. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as renal cyst, polycystic kidney, extensive abdominal edema, uroclepsia, hematuria, albuminuria, urinary tract infection, malaise, loss of appetite, dreaminess, insomnia, amnesia and the like. The Chinese medicinal composition has the advantages of exact clinical effects, obvious curative effect, quick response, low cost, basically no toxic or side effects and the like because the Chinese medicinal composition basically combines medicaments having homology of medicament and food specified in national formulary.

The subject invention relates to methods for detection of mutations in a PKD gene using DHPLC. The invention includes the following aspects: identification of PKD unique sites; design of PKD-specific primers; amplification of PKD-specific products; and analysis of PCR amplified products by DHPLC. The invention further relates to compositions such as identified unique sites and PKD-specific primers, and kits for performing the methods of the invention.

A composite medicine for treating polycystic kidney disease contains the epoxidase 2(COX-2) specific depressant and the thiazolidbione-type medicine.

The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EDF receptor kinase inhibitor.

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPARγ agonist, through activating PPAR-RXR heterodimers that intereacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer.

The invention relates to a detection method of adult type polycystic kidney. The treatment mutation of adult type polycystic kidney disease-causing genes PKD1 and PKD2 is detected and identified by adopting a long fragment PCR (Polymerase Chain Reaction) capturing, second generation sequencing and first generation identification. Compared with an existing probe capturing technology, true and false genes can be distinguished, real genes are specifically captured and interference caused by the false genes is reduced; the ratio of all components is optimized and the consistency of capturing is ensured; the conditions that the uniformity of data is poor and the data quantity of partial segments is not enough are avoided; an optimized database building scheme has good stability and automatic database building is convenient to carry out; after an existing analysis method is tested, a detection result can be processed very well and a correct result is found.

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPARγ agonist, through activating PPAR-RXR heterodimers that interacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer.

The present invention discloses a kind of Chinese medicine composition for treating ovary cyst, polycystic kidney cyst, liver cyst and brain cyst. The Chinese medicine composition is prepared with burreed rhizome and safflower. Clinical application shows that the Chinese medicine composition has total effective rate of treating cyst as high as 100 % and no obvious side effect.

The invention discloses an STR locus of a PKD1 gene. The STR locus has a nucleic acid sequence shown by SEQ ID NO.1 or SEQ ID NO.2. The invention also discloses an application of the STR locus of the PKD1 gene, wherein the STR locus is applied to the preplantation genetile diagnosis or prenatal diagnosis of autosomal dominant polycystic kidney. With higher resolution, the STR locus of the PKD1 gene disclosed by the invention is applied to the linkage heredity analysis of the PKD1 gene, can be used for remarkably improving the typing recognition efficiency and accuracy, and provides a basis for clinical preplantation genetile diagnosis of autosomal dominant polycystic kidney.

The invention relates to the technical field of medicine, in particular to a medicine composition which consists of rosiglitazone and amiloride and can be used for treating polycystic kidneys or typeII diabetes. The rosiglitazone is widely applied to treating the type II diabetes, but has obvious side effect on the heart if application for a long time. The invention provides a medicine composition consisting of rosiglitazone and amiloride, which has obvious treatment effect on an Han:SPRD rat of a polycystic model animal without producing obvious side effects on the heart through animal experiments; the treatment for the mouse model suffered from the type II diabetes shows that: the medicine composition can obviously reduce the side effect of the rosiglitazone on the heart while treatingthe type II diabetes, thereby being used for preparing a medicament for treating the polycystic kidneys or type II diabetes. The invention provides a better prospect for the treatment of the polycystic kidneys or type II diabetes.

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and / or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and / or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

The invention discloses an external traditional Chinese medicine prescription for treating polycystic kidney and a preparation method of an external traditional Chinese medicine prescription, relating to the technical field of traditional Chinese medicines for treating polycystic kidney. The external traditional Chinese medicine prescription is mainly prepared from powder of the following traditional Chinese medicine raw materials in parts by weight: 15-45 parts of herba centellae, 25-65 parts of artemisia anomala, 5-35 parts of salvia chinensis, 2-23 parts of spina gleditsiae, 15-55 parts of verbena officinals, 20-55 parts of fructus polygoni orientalis, 2-15 parts of semen plantaginis, 4-17 parts of bamboo leaves, 5-15 parts of phellodendron chinense schneid, 30-65 parts of rhizoma corydalis, 1-13 parts of dried lacquer, 2-13 parts of common rush and 20-35 parts of euphorbia humifusa. The external traditional Chinese medicine prescription is safe and reliable, non-invasive, painless, low in cost, short in treatment course, fast to act, and capable of resolving dampness, heat and toxicity, the preparation method is simple, the treatment effect on the patients with polycystic kidney is significant, and the effective rate is more than 95%.

The invention discloses Chinese herbal medicine composition for treating the polycystic kidney. The Chinese herbal medicine composition comprises the following components of suncured ginseng, roasted rhizoma atractylodis macrocephalae, radix aconiti lateralis preparata, cornua cervi pantotrichum, roasted morinda officinalis, processed mangnolia officinalis, radix curcumae, roasted turtle shells, mirabilite, endothelium corneum gigeriae galli, hirudo, processed rhizoma sparganii, processed curcuma zedoary, pseudo-ginseng, radix cyathulae, semen brassicae, saposhnicovia divaricata, caulis sinomenii, roasted semen plantaginis and roasted rhizoma alismatis. The invention further discloses a preparation method of the Chinese herbal medicine composition for treating the polycystic kidney. The preparation method comprises the steps of weighing, medicine washing and airing, processing and mixed grinding, and the Chinese herbal medicine composition is obtained. The composition can enable the cysts of the polycystic kidney to be controlled or reduced, a patient is protected from the pain of an operation, and the renal function is protected. Living quality is improved, and life time is prolonged.

The present invention relates to medicine molecular biology engineering technology, and is one kind of 1N-end fusion protein PC-1-e2 of human polycystic protein-1. According to cDNA sequence of human polycystic kidney disease-1 gene and the molecular structure of its encoded product, polycystic protein-1 (PC-1), the gene is cloned to cDNA-PKD1e2 in the N end of the protein and its prokaryotic expression carrier pQE30-PKD1e2 is constituted by means of molecular biology engineering technology. N-end fusion protein PC-1-e2 of PC-1 is induced in colibacillus. Cytobiology experiment shows that the fusion protein has obvious inhibition to the proliferation of the epidermis cell line of in vitro cultured human polycystic kidney cyst lining and the epidermis cell strain of far end renal tubule in dog kidney, so that it may be used in preparing medicine for treating autosomal dominant hereditary polycystic kidney disease, the reagent for the mechanism research of the disease, and anti-PC-1 antibody.

The present invention relates to the application of pyrimidone compounds in preparing medicine for treating secreted diarrhea and autosomal dominant inheritance polycystic kidney disease. Cystic fibrosis transmembrane conductance regulator (CFTR) factor is one kind of chloridion channel protein activated with cyclic adenosine monophosphate, and during designing model, several CFTR activating ways are considered and applied in the screening process, so as to screen out pyrimidone compounds to prepare medicine for treating secreted diarrhea and autosomal dominant inheritance polycystic kidney disease. The present invention can prevent and treat swine diarrhea effectively and inhibit the liquid secretion of epidermis cell of autosomal dominant inheritance polycystic kidney cyst lining, without obvious toxicity.

Combination of antagonists of the vasopressin receptor and calciomimetics and composition comprising it, and its use for the prevention and / or treatment of polycystic kidney.

The invention discloses a novel Chinese medicinal composition for treating renal cyst diseases and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: mix-fried pangolin scales, tangerine peel, Chinese angelica, immature bitter orange, common burreed rhizome, zedoary, turmeric root-tuber, peach seed, safflower, turtle shell, tortoise plastron, Szechuan lovage rhizome, red paeony root, dragon's blood, Chinese eaglewood, green tangerine peel, root of red-rooted salvia, Indian buead, oriental waterplantain rhizome, cortex lyciiradicis, amur corktree bark, gardenia, Vietnamese sophora root, raw rehmannia root, liriope, coridius, nutgrass galingale rhizome, medicated leaven and plantain seed. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as renal cyst, polycystic kidney, extensive abdominal edema, uroclepsia, hematuria, albuminuria, urinary tract infection, malaise, loss of appetite, dreaminess, insomnia, amnesia and the like. The Chinese medicinal composition has the advantages of exact clinical effects, obvious curative effect, quick response, low cost, basically no toxic or side effects and the like because the Chinese medicinal composition basically combines medicaments having homology of medicament and food specified in national formulary.

This document provides methods and materials for using natriuretic polypeptides to reduce the generation of kidney cysts, to reduce the number of kidney cysts, to reduce the size of kidney cysts, and / or to reduce the weight of a mammal's kidneys in mammals with polycystic kidney disease. For example, methods and materials for using natriuretic polypeptides (e.g., BNP) and / or nucleic acid encoding natriuretic polypeptides to reduce kidney cystogenesis and to reduce kidney organ to body weight ratios in mammals with mammals with polycystic kidney disease (e.g., autosomal recessive polycystic kidney disease) are provided.

In order to determine epigenetic variations of autosomal dominant polycystic kidney disease and functional association therebetween, the present inventors have subjected individuals with polycystic kidney disease and without polycystic kidney disease to analysis through methylation profiling in random fashion of the genome as a whole. Interestingly, in PKD1 and other genes associated with ion transport and cell adhesion, there was hypermethylation in the gene-body region, and the expression of these genes was down-regulated in polycystic kidney disease. In particular, in PKD1, there was hypermethylation in the polycystic kidney disease gene-body region, and this was associated with MBD2 (methyl-CpG-binding domain 2) protein binding. In addition, DNA methylation inhibitor treatment was accompanied by up-regulation of PKD1 expression and caused a delay in cyst formation in MDCK (Madin-Darby Canine Kidney) cells. This therefore demonstrates that, in the present invention, hypermethylation of PKD1 and regulator genes associated with cyst formation plays a decisive role in cyst formation and shows that the present invention can be used in therapeutic applications for autosomal dominant polycystic kidney disease.

The invention comprises use of a therapeutically effective amount of the compound of the formula below for preparation of a medicament for treating polycystic kidney diseases (PKD) in a mammal, such as human or feline (e.g., Persian cat).Formula (I). Also provided are the above compound and compositions comprising it for treating PKD.

In order to determine the epigenetic mutation of autosomal dominant polycystic kidney disease and its functional relevance, the present inventors randomly analyzed the whole genome of polycystic kidney disease and non-polycystic kidney disease individuals by methylation profiling method and compared with their performance data. Interestingly, PKD1 and other genes associated with ion transport and cell binding were hypermethylated at the gene body, which was downregulated in polycystic kidney disease. In particular, PKD1 is partially hypermethylated in the polycystic kidney gene body, which is associated with MBD2 (methyl‑CpG‑binding domain 2) protein binding. Furthermore, DNA methylation inhibitor treatment was accompanied by an upregulation of PKD1 expression and delayed cyst formation in MDCK (Madin‑Darby Canine Kidney) cells. Thus, hypermethylation of PKD1 and cyst formation-associated regulatory genes of the present invention is decisive for cyst formation and revealed to be useful as a treatment for autosomal dominant polycystic kidney disease.

The present invention provides compositions and methods for detecting mutations associated with polycystic kidney disease in the cat.

A major gene of a pc mutant of a Japanese Medaka fish (Oryzias latipes) has been identified. Based on this finding, use of the gene is provided. A gene responsible for polycystic kidney in a Japanese Medaka fish is identified in the chromosomal region of the fish by performing a positional cloning on a pc mutant of the fish. The pc gene is a transcription factor having five C2H2-type zind finger regions, and is considered to be a gene homologous to human Gli-similar 3 (Glis3) gene since it shows a high homology in the zinc finger regions.